A newly released cache of internal Food and Drug Administration memos shows that Dr. Vinay Prasad, the agency’s recently appointed vaccine chief, overruled staff scientists to narrow the authorization of two COVID-19 vaccines made by Novavax and Moderna.

FDA reviewers had recommended clearing both shots for everyone aged 12 and older after concluding the benefits outweighed the low risk of side effects. In a five-page override memo dated 2 July, Prasad instead limited the vaccines to seniors and people with underlying health conditions, citing falling hospitalization and death rates and lingering questions about rare cases of myocarditis.

Read more

Moderna Inc. announced positive results from its Phase 3 clinical trial of the mRNA-1010 seasonal influenza vaccine. The study, involving approximately 56,000 volunteers aged 50 and older, demonstrated that the experimental vaccine was about 27% more effective than an existing approved flu shot from GlaxoSmithKline (GSK). The vaccine showed strong efficacy across all strains of influenza with no major safety concerns reported.

These results support Moderna's broader strategy of developing combination vaccines, including potential future formulations that combine COVID-19 and influenza protection. Following the announcement, Moderna's shares rose between 2% and 7.4% in various trading sessions. The company indicated that it plans to file submissions with regulatory agencies later this year based on the positive late-stage trial outcomes.

Moderna said its mRNA-based influenza vaccine, mRNA-1010, generated a significantly stronger immune response than a currently licensed shot in a late-stage study involving more than 40,000 adults aged 50 and older. The candidate reduced confirmed flu cases by 26.6% compared with the standard vaccine across the full study population and by 27.4% in adults 65 and above, a group at higher risk of severe illness. Efficacy was consistent across major circulating strains A/H1N1, A/H3N2 and B/Victoria.

Read more

U.S. Senator Bill Cassidy, a Republican from Louisiana and chair of the Senate Committee on Health, Education, Labor and Pensions, has called for the postponement of a scheduled meeting of the Centers for Disease Control and Prevention's (CDC) vaccine advisory panel. The meeting, planned for Wednesday, was convened under the direction of Health and Human Services Secretary Robert F. Kennedy Jr., who recently replaced several CDC vaccine advisers with new appointees.

Cassidy, who had previously voted to confirm Kennedy as HHS Secretary, expressed concerns that some of Kennedy's appointees lack experience with new vaccine technologies such as mRNA vaccines and may hold preconceived biases against certain vaccines. He urged that the meeting should not proceed until more members with relevant expertise are appointed to the panel. Cassidy's call to delay the meeting is seen as a challenge to Kennedy's approach to managing the federal vaccine advisory committee.

The US Food and Drug Administration has broadened the label for Moderna’s respiratory syncytial virus vaccine, mRESVIA (mRNA-1345), authorizing its use in adults aged 18 to 59 who have chronic health conditions or other factors that put them at higher risk of severe RSV illness. The shot was cleared last year for adults 60 and older.

The ruling extends the reach of Moderna’s first non-Covid product built on its mRNA platform and follows the agency’s authorization of the company’s updated Covid-19 vaccine earlier this month. Analysts said the decision may signal a softening of the Trump administration’s earlier reservations about mRNA technology.

Read more

Robert Malone, a controversial figure known for his early work in mRNA research and claims of inventing the technology, has been appointed to the CDC’s vaccine advisory panel by Robert F. Kennedy Jr. Malone gained prominence during the COVID-19 pandemic, particularly following a 2021 appearance on The Joe Rogan Experience where he made statements that were widely criticized by healthcare professionals and accused of spreading misinformation. His views have been associated with conspiracy theories regarding the pandemic and vaccines. Alongside Malone, Martin Kulldorff, coauthor of the Great Barrington Declaration, was also named to the panel, raising concerns among experts about the future direction of vaccine policy under the new advisory board.

Calls have intensified for Secretary Kennedy to ban the mRNA vaccine platform in the United States. Critics are demanding the removal of this technology, citing concerns over its safety and impact. The discourse includes demands for accountability related to the approval and promotion of mRNA vaccines, with some individuals questioning whether those responsible for endorsing the vaccines will face consequences. Additionally, there are broader calls for legal actions connected to various political and social controversies, including investigations into events such as the January 6 incident and alleged riots, though no specific charges have been reported in these areas.

Robert F. Kennedy Jr. has taken a controversial stance against mRNA vaccines, declaring them unsafe and ineffective. In a recent move, he dismissed the entire Advisory Committee on Immunization Practices (ACIP) at the Centers for Disease Control and Prevention (CDC), a panel that had previously made unanimous decisions supporting vaccine use, including for children.

Two members who had expressed dissent had already resigned prior to the committee's dismissal. Kennedy's actions and statements have drawn criticism and sparked debate, with some describing his approach as lacking understanding. His public opposition to mRNA vaccines has also impacted the stock prices of vaccine manufacturers Moderna and Pfizer. Kennedy's rationale for these decisions was outlined in an article that has not been widely referenced in media coverage. Additionally, his stance has prompted responses from public health advocates, including an open letter addressing his views on mRNA technology.

Researchers have announced promising advancements in medical science with the development of a vaccine aimed at preventing cancer recurrence and a novel method to target HIV by activating its latent cellular reservoirs. The vaccine designed to combat cancer relapse has shown highly encouraging results, marking a breakthrough in medical technology that also accelerates the development timeline for targeted vaccines. Concurrently, scientists have reported a significant step forward in the search for an HIV cure, successfully extracting the virus from its 'cellular hiding place,' which has generated optimism in the scientific community. Despite these advances, some skepticism remains regarding the durability of the HIV breakthrough. Additionally, there is ongoing debate in several US states and parts of Canada about the use of mRNA technology, which has been employed in COVID-19 vaccines and is now being explored for its potential to eliminate HIV from the body.

Recent studies and expert commentary have raised concerns about the potential reproductive and health risks associated with mRNA COVID-19 vaccines. Two studies reportedly found that mRNA vaccines can destroy over half of a woman’s non-renewable egg supply and reduce conception success by 33%. Additional claims suggest these vaccines may cause immune system reprogramming linked to Vaccine-Acquired Immune Deficiency Syndrome (VAIDS), increasing risks of infections, cancer, and autoimmune diseases. Specific allegations include associations between mRNA vaccines and various cancers such as leukemia, lymphoma, brain, breast, colon, and lung cancers, as well as heart disease.

Medical experts have also reported the discovery of fibrous, prion-like clots in young children born to mothers vaccinated with mRNA shots during pregnancy. These findings have prompted criticism of current vaccine guidance for pregnant women, with calls for greater transparency and informed consent. Meanwhile, the European Union has approved a self-amplifying mRNA vaccine, KOSTAIVE® (ARCT-154), despite ongoing debates about the long-term safety data of mRNA vaccine technology.

Researchers at Australia's Peter Doherty Institute for Infection and Immunity in Melbourne have developed a novel method to activate dormant HIV within white blood cells, a breakthrough previously considered impossible. This technique uses mRNA technology, similar to that employed in COVID-19 vaccines, to "wake up" hidden HIV reservoirs in the body. The activation of these latent viruses is a critical step toward their complete eradication, potentially bringing the medical community closer to a definitive cure for HIV. The advancement addresses a major challenge in HIV treatment, as the virus can remain hidden in immune cells, evading current therapies. This development has generated international attention as a promising avenue in the ongoing fight against HIV/AIDS.

Robert F. Kennedy Jr., serving as Health Secretary, has appointed David Geier, an antivaccine activist, to investigate federal records for evidence suggesting that vaccines cause autism. This initiative aims to uncover alleged concealment of such evidence by federal officials. The investigation has raised concerns about potential impacts on vaccine manufacturers, including Moderna and Pfizer. Critics have described the move as promoting pseudoscience and expressed apprehension about its implications for public health policy.

The U.S. Food and Drug Administration (FDA) has approved Moderna's next-generation mRNA COVID-19 vaccine, named mNEXSPIKE, targeting individuals with certain risk factors. Despite the approval, top officials from the FDA have clarified that the agency is not recommending the vaccine for the general public. Concerns have been raised by medical experts about the introduction of new mRNA vaccines, particularly with the emergence of self-amplifying mRNA technology. Critics point out that the mNEXSPIKE vaccine has not undergone randomized controlled trials and has not been evaluated for potential cancer risks. The FDA emphasized that it does not act as a personal healthcare provider and its approval does not equate to a direct recommendation for vaccination.

A lawsuit has been filed against US Health Secretary Robert F. Kennedy Jr. and Elon Musk, alleging that the Department of Government Efficiency (DOGE) and the Department of Health and Human Services (HHS) relied on flawed and error-ridden personnel data to terminate 10,000 federal employees. The fired workers, including former HHS and FDA staff, claim that the terminations were based on inaccurate records and that their privacy rights were violated during the process. The lawsuit highlights allegations that the data used for the mass layoffs was hopelessly flawed, raising concerns about the handling of personnel information and compliance with federal privacy laws.

Health and Human Services Secretary Robert F. Kennedy Jr. announced that Moderna has agreed to conduct a true placebo-controlled trial for its newly approved mRNA COVID-19 vaccine, which is authorized for use in high-risk populations. The U.S.

Food and Drug Administration (FDA) granted limited approval to this vaccine without a prior placebo-controlled trial, but will monitor and collect data on every adverse outcome throughout the trial period. This new vaccine is similar to the existing mRNA vaccine but uses a smaller dosage. Meanwhile, the self-replicating saRNA COVID-19 vaccine continues to be fast-tracked by the administration, despite warnings from some scientists about its potential risks compared to the mRNA platform.

Health and Human Services Secretary Robert F. Kennedy Jr. announced a significant change in the Centers for Disease Control and Prevention's (CDC) recommendations for the COVID-19 vaccine. The update removes the vaccine from the recommended immunization schedule for healthy children and pregnant women, marking a departure from previous guidelines. This decision reflects a shift in policy under the Trump administration, which has been critical of mRNA technology.

Read more

The U.S. Department of Health and Human Services (HHS) recently stated that mRNA technology remains under-tested, emphasizing concerns about safety, integrity, and public trust. This position reflects a cautious approach to further investment in mRNA biologics, citing lessons from previous administrations. HHS communications director Andrew Nixon highlighted the need to reconsider the widespread use of mRNA injections, which were administered to approximately 80% of the U.S.

population during the COVID-19 pandemic. The department's stance has prompted calls from some medical professionals and commentators to remove mRNA vaccines from the market and conduct additional trials to ensure safety. Moderna responded by defending mRNA technology, pointing to its demonstrated efficacy and safety profile in over a billion people worldwide during the pandemic. Meanwhile, Pfizer's CEO refuted HHS claims of concealed safety concerns regarding mRNA vaccines, labeling them as completely inaccurate. Concerns have also been raised about novel self-replicating mRNA vaccines, with warnings about potential systemic toxicity and regulatory shortcuts. The debate highlights ongoing tensions between regulatory caution and pharmaceutical industry assurances over mRNA vaccine safety and readiness.

Health and Human Services Secretary Robert F. Kennedy Jr. announced plans that could bar government scientists from publishing their research in leading medical journals. Instead, he proposed creating "in-house" publications managed by his agency.

This move aligns with the Trump administration's broader approach to federal health policy. Additionally, the HHS spokesperson Andrew Nixon stated that the decision to terminate the contract with Moderna for an mRNA bird flu vaccine was based on concerns that mRNA technology remains "under-tested." The department emphasized that the decision was driven by considerations of safety, integrity, and trust, and a reluctance to repeat perceived mistakes of the previous administration. These developments highlight a shift in how the HHS intends to manage scientific communication and vaccine development under Kennedy's leadership.

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. and Argentine Health Minister Mario Lugones have jointly criticized the World Health Organization (WHO) as both countries confirmed their withdrawal from the global health body earlier this year.

During Kennedy's official visit to Buenos Aires, the two officials announced plans to establish an alternative international health system independent of the WHO, aiming to create a high-level scientific partnership free from political controls. This move aligns with Argentina’s President Javier Milei's decision to exit the WHO and pursue a strategic health alliance with the U.S. The U.S. administration under Kennedy has also taken controversial steps domestically, including canceling nearly $600 million in contracts with Moderna for pandemic-related vaccines and terminating multiple National Institutes of Health (NIH) research grants, including those related to ALS. These actions have drawn criticism from some lawmakers and public health experts who emphasize the safety and importance of vaccines. Kennedy has expressed support for alternative medicines such as stem cells, peptides, and vitamins, indicating a shift in FDA policy focus. The new U.S.-Argentina health initiative seeks to encourage other nations to join their alternative framework, signaling a notable realignment in international health governance.

FDA Commissioner Dr. Martin Makary has outlined a shift in U.S. health policy, emphasizing a move from a reactionary to a proactive approach, particularly in children's health. In recent interviews, Makary discussed the Make America Healthy Again (MAHA) initiative, which aims to address the root causes of chronic diseases in American children.

Makary stated that the FDA will no longer automatically approve annual COVID-19 vaccine boosters for teenagers without updated clinical trial data, signaling an end to the previous practice of routinely authorizing such vaccines. He described the theory that young, healthy individuals need numerous COVID-19 boosters throughout their lives as unproven.

Read more

A newly released cache of internal Food and Drug Administration memos shows that Dr. Vinay Prasad, the agency’s recently appointed vaccine chief, overruled staff scientists to narrow the authorization of two COVID-19 vaccines made by Novavax and Moderna.

FDA reviewers had recommended clearing both shots for everyone aged 12 and older after concluding the benefits outweighed the low risk of side effects. In a five-page override memo dated 2 July, Prasad instead limited the vaccines to seniors and people with underlying health conditions, citing falling hospitalization and death rates and lingering questions about rare cases of myocarditis.

Read more

Moderna Inc. announced positive results from its Phase 3 clinical trial of the mRNA-1010 seasonal influenza vaccine. The study, involving approximately 56,000 volunteers aged 50 and older, demonstrated that the experimental vaccine was about 27% more effective than an existing approved flu shot from GlaxoSmithKline (GSK). The vaccine showed strong efficacy across all strains of influenza with no major safety concerns reported.

These results support Moderna's broader strategy of developing combination vaccines, including potential future formulations that combine COVID-19 and influenza protection. Following the announcement, Moderna's shares rose between 2% and 7.4% in various trading sessions. The company indicated that it plans to file submissions with regulatory agencies later this year based on the positive late-stage trial outcomes.

Moderna said its mRNA-based influenza vaccine, mRNA-1010, generated a significantly stronger immune response than a currently licensed shot in a late-stage study involving more than 40,000 adults aged 50 and older. The candidate reduced confirmed flu cases by 26.6% compared with the standard vaccine across the full study population and by 27.4% in adults 65 and above, a group at higher risk of severe illness. Efficacy was consistent across major circulating strains A/H1N1, A/H3N2 and B/Victoria.

Read more

U.S. Senator Bill Cassidy, a Republican from Louisiana and chair of the Senate Committee on Health, Education, Labor and Pensions, has called for the postponement of a scheduled meeting of the Centers for Disease Control and Prevention's (CDC) vaccine advisory panel. The meeting, planned for Wednesday, was convened under the direction of Health and Human Services Secretary Robert F. Kennedy Jr., who recently replaced several CDC vaccine advisers with new appointees.

Cassidy, who had previously voted to confirm Kennedy as HHS Secretary, expressed concerns that some of Kennedy's appointees lack experience with new vaccine technologies such as mRNA vaccines and may hold preconceived biases against certain vaccines. He urged that the meeting should not proceed until more members with relevant expertise are appointed to the panel. Cassidy's call to delay the meeting is seen as a challenge to Kennedy's approach to managing the federal vaccine advisory committee.

The US Food and Drug Administration has broadened the label for Moderna’s respiratory syncytial virus vaccine, mRESVIA (mRNA-1345), authorizing its use in adults aged 18 to 59 who have chronic health conditions or other factors that put them at higher risk of severe RSV illness. The shot was cleared last year for adults 60 and older.

The ruling extends the reach of Moderna’s first non-Covid product built on its mRNA platform and follows the agency’s authorization of the company’s updated Covid-19 vaccine earlier this month. Analysts said the decision may signal a softening of the Trump administration’s earlier reservations about mRNA technology.

Read more

Robert Malone, a controversial figure known for his early work in mRNA research and claims of inventing the technology, has been appointed to the CDC’s vaccine advisory panel by Robert F. Kennedy Jr. Malone gained prominence during the COVID-19 pandemic, particularly following a 2021 appearance on The Joe Rogan Experience where he made statements that were widely criticized by healthcare professionals and accused of spreading misinformation. His views have been associated with conspiracy theories regarding the pandemic and vaccines. Alongside Malone, Martin Kulldorff, coauthor of the Great Barrington Declaration, was also named to the panel, raising concerns among experts about the future direction of vaccine policy under the new advisory board.

Calls have intensified for Secretary Kennedy to ban the mRNA vaccine platform in the United States. Critics are demanding the removal of this technology, citing concerns over its safety and impact. The discourse includes demands for accountability related to the approval and promotion of mRNA vaccines, with some individuals questioning whether those responsible for endorsing the vaccines will face consequences. Additionally, there are broader calls for legal actions connected to various political and social controversies, including investigations into events such as the January 6 incident and alleged riots, though no specific charges have been reported in these areas.

Robert F. Kennedy Jr. has taken a controversial stance against mRNA vaccines, declaring them unsafe and ineffective. In a recent move, he dismissed the entire Advisory Committee on Immunization Practices (ACIP) at the Centers for Disease Control and Prevention (CDC), a panel that had previously made unanimous decisions supporting vaccine use, including for children.

Two members who had expressed dissent had already resigned prior to the committee's dismissal. Kennedy's actions and statements have drawn criticism and sparked debate, with some describing his approach as lacking understanding. His public opposition to mRNA vaccines has also impacted the stock prices of vaccine manufacturers Moderna and Pfizer. Kennedy's rationale for these decisions was outlined in an article that has not been widely referenced in media coverage. Additionally, his stance has prompted responses from public health advocates, including an open letter addressing his views on mRNA technology.

Researchers have announced promising advancements in medical science with the development of a vaccine aimed at preventing cancer recurrence and a novel method to target HIV by activating its latent cellular reservoirs. The vaccine designed to combat cancer relapse has shown highly encouraging results, marking a breakthrough in medical technology that also accelerates the development timeline for targeted vaccines. Concurrently, scientists have reported a significant step forward in the search for an HIV cure, successfully extracting the virus from its 'cellular hiding place,' which has generated optimism in the scientific community. Despite these advances, some skepticism remains regarding the durability of the HIV breakthrough. Additionally, there is ongoing debate in several US states and parts of Canada about the use of mRNA technology, which has been employed in COVID-19 vaccines and is now being explored for its potential to eliminate HIV from the body.

Recent studies and expert commentary have raised concerns about the potential reproductive and health risks associated with mRNA COVID-19 vaccines. Two studies reportedly found that mRNA vaccines can destroy over half of a woman’s non-renewable egg supply and reduce conception success by 33%. Additional claims suggest these vaccines may cause immune system reprogramming linked to Vaccine-Acquired Immune Deficiency Syndrome (VAIDS), increasing risks of infections, cancer, and autoimmune diseases. Specific allegations include associations between mRNA vaccines and various cancers such as leukemia, lymphoma, brain, breast, colon, and lung cancers, as well as heart disease.

Medical experts have also reported the discovery of fibrous, prion-like clots in young children born to mothers vaccinated with mRNA shots during pregnancy. These findings have prompted criticism of current vaccine guidance for pregnant women, with calls for greater transparency and informed consent. Meanwhile, the European Union has approved a self-amplifying mRNA vaccine, KOSTAIVE® (ARCT-154), despite ongoing debates about the long-term safety data of mRNA vaccine technology.

Researchers at Australia's Peter Doherty Institute for Infection and Immunity in Melbourne have developed a novel method to activate dormant HIV within white blood cells, a breakthrough previously considered impossible. This technique uses mRNA technology, similar to that employed in COVID-19 vaccines, to "wake up" hidden HIV reservoirs in the body. The activation of these latent viruses is a critical step toward their complete eradication, potentially bringing the medical community closer to a definitive cure for HIV. The advancement addresses a major challenge in HIV treatment, as the virus can remain hidden in immune cells, evading current therapies. This development has generated international attention as a promising avenue in the ongoing fight against HIV/AIDS.

Robert F. Kennedy Jr., serving as Health Secretary, has appointed David Geier, an antivaccine activist, to investigate federal records for evidence suggesting that vaccines cause autism. This initiative aims to uncover alleged concealment of such evidence by federal officials. The investigation has raised concerns about potential impacts on vaccine manufacturers, including Moderna and Pfizer. Critics have described the move as promoting pseudoscience and expressed apprehension about its implications for public health policy.

The U.S. Food and Drug Administration (FDA) has approved Moderna's next-generation mRNA COVID-19 vaccine, named mNEXSPIKE, targeting individuals with certain risk factors. Despite the approval, top officials from the FDA have clarified that the agency is not recommending the vaccine for the general public. Concerns have been raised by medical experts about the introduction of new mRNA vaccines, particularly with the emergence of self-amplifying mRNA technology. Critics point out that the mNEXSPIKE vaccine has not undergone randomized controlled trials and has not been evaluated for potential cancer risks. The FDA emphasized that it does not act as a personal healthcare provider and its approval does not equate to a direct recommendation for vaccination.

A lawsuit has been filed against US Health Secretary Robert F. Kennedy Jr. and Elon Musk, alleging that the Department of Government Efficiency (DOGE) and the Department of Health and Human Services (HHS) relied on flawed and error-ridden personnel data to terminate 10,000 federal employees. The fired workers, including former HHS and FDA staff, claim that the terminations were based on inaccurate records and that their privacy rights were violated during the process. The lawsuit highlights allegations that the data used for the mass layoffs was hopelessly flawed, raising concerns about the handling of personnel information and compliance with federal privacy laws.

Health and Human Services Secretary Robert F. Kennedy Jr. announced that Moderna has agreed to conduct a true placebo-controlled trial for its newly approved mRNA COVID-19 vaccine, which is authorized for use in high-risk populations. The U.S.

Food and Drug Administration (FDA) granted limited approval to this vaccine without a prior placebo-controlled trial, but will monitor and collect data on every adverse outcome throughout the trial period. This new vaccine is similar to the existing mRNA vaccine but uses a smaller dosage. Meanwhile, the self-replicating saRNA COVID-19 vaccine continues to be fast-tracked by the administration, despite warnings from some scientists about its potential risks compared to the mRNA platform.

Health and Human Services Secretary Robert F. Kennedy Jr. announced a significant change in the Centers for Disease Control and Prevention's (CDC) recommendations for the COVID-19 vaccine. The update removes the vaccine from the recommended immunization schedule for healthy children and pregnant women, marking a departure from previous guidelines. This decision reflects a shift in policy under the Trump administration, which has been critical of mRNA technology.

Read more

The U.S. Department of Health and Human Services (HHS) recently stated that mRNA technology remains under-tested, emphasizing concerns about safety, integrity, and public trust. This position reflects a cautious approach to further investment in mRNA biologics, citing lessons from previous administrations. HHS communications director Andrew Nixon highlighted the need to reconsider the widespread use of mRNA injections, which were administered to approximately 80% of the U.S.

population during the COVID-19 pandemic. The department's stance has prompted calls from some medical professionals and commentators to remove mRNA vaccines from the market and conduct additional trials to ensure safety. Moderna responded by defending mRNA technology, pointing to its demonstrated efficacy and safety profile in over a billion people worldwide during the pandemic. Meanwhile, Pfizer's CEO refuted HHS claims of concealed safety concerns regarding mRNA vaccines, labeling them as completely inaccurate. Concerns have also been raised about novel self-replicating mRNA vaccines, with warnings about potential systemic toxicity and regulatory shortcuts. The debate highlights ongoing tensions between regulatory caution and pharmaceutical industry assurances over mRNA vaccine safety and readiness.

Health and Human Services Secretary Robert F. Kennedy Jr. announced plans that could bar government scientists from publishing their research in leading medical journals. Instead, he proposed creating "in-house" publications managed by his agency.

This move aligns with the Trump administration's broader approach to federal health policy. Additionally, the HHS spokesperson Andrew Nixon stated that the decision to terminate the contract with Moderna for an mRNA bird flu vaccine was based on concerns that mRNA technology remains "under-tested." The department emphasized that the decision was driven by considerations of safety, integrity, and trust, and a reluctance to repeat perceived mistakes of the previous administration. These developments highlight a shift in how the HHS intends to manage scientific communication and vaccine development under Kennedy's leadership.

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. and Argentine Health Minister Mario Lugones have jointly criticized the World Health Organization (WHO) as both countries confirmed their withdrawal from the global health body earlier this year.

During Kennedy's official visit to Buenos Aires, the two officials announced plans to establish an alternative international health system independent of the WHO, aiming to create a high-level scientific partnership free from political controls. This move aligns with Argentina’s President Javier Milei's decision to exit the WHO and pursue a strategic health alliance with the U.S. The U.S. administration under Kennedy has also taken controversial steps domestically, including canceling nearly $600 million in contracts with Moderna for pandemic-related vaccines and terminating multiple National Institutes of Health (NIH) research grants, including those related to ALS. These actions have drawn criticism from some lawmakers and public health experts who emphasize the safety and importance of vaccines. Kennedy has expressed support for alternative medicines such as stem cells, peptides, and vitamins, indicating a shift in FDA policy focus. The new U.S.-Argentina health initiative seeks to encourage other nations to join their alternative framework, signaling a notable realignment in international health governance.

FDA Commissioner Dr. Martin Makary has outlined a shift in U.S. health policy, emphasizing a move from a reactionary to a proactive approach, particularly in children's health. In recent interviews, Makary discussed the Make America Healthy Again (MAHA) initiative, which aims to address the root causes of chronic diseases in American children.

Makary stated that the FDA will no longer automatically approve annual COVID-19 vaccine boosters for teenagers without updated clinical trial data, signaling an end to the previous practice of routinely authorizing such vaccines. He described the theory that young, healthy individuals need numerous COVID-19 boosters throughout their lives as unproven.

Read more